Cargando…

Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine

Four large trials have recently evaluated the effects of anti-inflammatory drugs in the secondary prevention of major cardiovascular events (MACE) in over 25 000 patients followed for 1.9–3.7 years. CANTOS tested subcutaneous canakinumab [an anti-interleukin (IL) 1β antibody] 300 mg every 3 months a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreotti, Felicita, Maggioni, Aldo Pietro, Campeggi, Alice, Iervolino, Adelaide, Scambia, Giovanni, Massetti, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503530/ https://www.ncbi.nlm.nih.gov/pubmed/34650351 http://dx.doi.org/10.1093/eurheartj/suab084

Ejemplares similares

Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes
por: Andreotti, Felicita, et al.
Publicado: (2021)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects
por: Calabria, Silvia, et al.
Publicado: (2022)

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF
por: Gul, A, et al.
Publicado: (2015)

Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies
por: Iervolino, Adelaide, et al.
Publicado: (2022)

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015)

Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

Colchicine and the heart
por: Imazio, Massimo, et al.
Publicado: (2021)

Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure
por: Maggioni, Aldo P., et al.
Publicado: (2021)

COVID-19 trials in Italy: A call for simplicity, top standards and global pooling
por: Maggioni, Aldo P., et al.
Publicado: (2020)

Methodological education in response to the quality of COVID-19 publications
por: Andreotti, Felicita, et al.
Publicado: (2021)

Development of focal segmental glomerulosclerosis in a patient with Familial Mediterranean Fever resistant to colchicine therapy under treatment with Canakinumab
por: Barut, K, et al.
Publicado: (2015)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
por: Ozen, Seza, et al.
Publicado: (2020)

Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants
por: Maggioni, Aldo Pietro, et al.
Publicado: (2021)

Anti‐inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy
por: Li, Yuyu, et al.
Publicado: (2021)

Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease
por: Shaul, Eliana, et al.
Publicado: (2022)

MicroRNAs in Valvular Heart Diseases: Biological Regulators, Prognostic Markers and Therapeutical Targets
por: Nappi, Francesco, et al.
Publicado: (2021)

Debate: Should statin be used in patients with heart failure?
por: Pietro Maggioni, Aldo
Publicado: (2001)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

The New Challenge for Heart Endocarditis: From Conventional Prosthesis to New Devices and Platforms for the Treatment of Structural Heart Disease
por: Nappi, Francesco, et al.
Publicado: (2021)

‘Precision medicine’ and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory)
por: Prati, Francesco, et al.
Publicado: (2019)

Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
por: Samuel, Michelle, et al.
Publicado: (2020)

Colchicine in ischemic heart disease: the good, the bad and the ugly
por: D’Amario, Domenico, et al.
Publicado: (2021)

Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
por: Bouabdallaoui, Nadia, et al.
Publicado: (2020)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Canakinumab for refractory RA: a case report
por: Marketos, Nikolaos, et al.
Publicado: (2018)

The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis
por: Golpour, Monireh, et al.
Publicado: (2021)

Protection of the ischaemic heart: investigations into the phenomenon of ischaemic preconditioning
por: Lochner, A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_84db4vih8q3ktf84i4ccbnfgt6